Cue Biopharma, Inc. (FRA:1UC0)

Market Cap	68.97M +64.0%
Revenue (ttm)	28.39M +309.6%
Net Income	-16.93M
EPS	-4.53
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	22.72
Previous Close	23.58
Day's Range	22.72 - 22.98
52-Week Range	4.35 - 30.76
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Cue Biopharma

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 29
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1UC0

Financial Performance

In 2025, Cue Biopharma's revenue was $27.47 million, an increase of 195.75% compared to the previous year's $9.29 million. Losses were -$26.60 million, -34.60% less than in 2024.

Financial numbers in USD